English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, May 24, 2023
米国臨床腫瘍学会年次総会におけるエーザイのがん領域の製品・開発品に関する発表について
Monday, May 22, 2023
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、英国(北アイルランドを除く)において早期アルツハイマー病に係る販売承認申請を提出
Saturday, May 20, 2023
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
Wednesday, May 17, 2023
エーザイ、臨床第III相Clarity AD試験データを用いた、日本における「レカネマブ」の社会的価値について、査読学術専門誌Neurology and Therapy誌に掲載
Tuesday, May 16, 2023
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
Monday, May 8, 2023
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
エーザイ、抗体薬物複合体BB-1701について、BlissBioと戦略的提携に向けたオプション権を有する共同開発契約を締結
Thursday, April 6, 2023
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
エーザイ、筑波研究所の大規模改修工事が竣工
Tuesday, April 4, 2023
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575